Special Issue "Cellular and Humoral Immunity after COVID-19 Vaccination"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 20035
Interests: hypertension; chronic kidney disease; acute kidney injury; renin-angiotensin system; kidney transplantation; hemodialysis; COVID-19; vaccination
The SARS-CoV-2 pandemic is spreading around the world with death and paralysis in healthcare systems. Vaccination is the safest and most effective tool to achieve a control the pandemic and build herd immunity. Vaccines against COVID-19 have been developed that are based on various platforms, including mRNA and DNA, inactivated viruses, live attenuated viruses, protein subunits, virus-like particles, and other viruses as vectors. The aim of vaccination is to generate a protective antibody titer to prevent infection and create long-term immune memory by the pool of memory cells, including T cells, high-affinity memory B cells, and plasma cells, all able to attenuate the severity of the disease course. Many aspects of the immune response following vaccination against COVID-19 remain unclear. This Special Issue of the Vaccines will summarize the current state of knowledge, fields to explore in particular referring (but not limited to) the following issues:
- cellular and humoral response in immunocompetent and immunocompromised population.
- differences in the immune response between vaccines
- duration of specific humoral and cellular immunity after primary and booster vaccination
- schemes of vaccination enhancing immune responses in immunocompromised patients
- comparing immune response after vaccination with the natural immunity of convalescents
- local and systemic reactogenicity and long-term safety of different vaccines
In this Special Issue, original research articles and reviews are welcome. We look forward to your contributions.
Prof. Dr. Leszek Tylicki
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- humoral immunity
- cellular immunity